Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Axonics Modulation Technologies Inc. (AXNX) on Thursday reported a third-quarter loss of $21,000, after reporting a profit in the same period a year earlier ...

Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ...

Shares of Axonics, Inc. (NASDAQ:AXNX – Get Free Report) have been given an average recommendation of “Hold” by the nine ...

On Friday, Axonics Inc (AXNX) stock saw a decline, ending the day at $70.23 which represents a decrease of $-0.05 or -0.07% from the prior close of $70.28. The stock opened at $70.3 and touched a low ...

Axonics Shares Fall Despite Australia's Approval for R20 SNM Device Axonics, Inc. (NASDAQ: AXNX) has received regulatory approval from the Therapeutic Goods Administration to market its R20 ...

In this article, we are going to take a look at where Axonics, Inc. (NASDAQ:AXNX) stands in the list of George Soros Net Worth and Top 10 Holdings in 2024. George Soros is one of the biggest ...

Axonics founder and CEO Raymond Cohen accepts a Business Journal Innovator of the Year award during a Sept. 12 ceremony. Axonics Inc. (Nasdaq: AXNX), a maker of medical devices to treat incontinence, ...

Axonics (NASDAQ:AXNX) quickly rose 1% after Boston Scientific (BSX) said it will no longer offer Coaptite as of Nov. 1. Investors believe the announcement may mean that Boston Scientific (BSX ...

Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The company had revenue of $114.57 million for the quarter, compared to analyst estimates of $112.83 million.